Mark W. Swaim

1.1k total citations · 1 hit paper
9 papers, 860 citations indexed

About

Mark W. Swaim is a scholar working on Hepatology, Epidemiology and Hematology. According to data from OpenAlex, Mark W. Swaim has authored 9 papers receiving a total of 860 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hepatology, 3 papers in Epidemiology and 3 papers in Hematology. Recurrent topics in Mark W. Swaim's work include Liver Disease and Transplantation (3 papers), Liver Disease Diagnosis and Treatment (3 papers) and Protease and Inhibitor Mechanisms (3 papers). Mark W. Swaim is often cited by papers focused on Liver Disease and Transplantation (3 papers), Liver Disease Diagnosis and Treatment (3 papers) and Protease and Inhibitor Mechanisms (3 papers). Mark W. Swaim collaborates with scholars based in United States and Taiwan. Mark W. Swaim's co-authors include Yehuda Z. Patt, Manal M. Hassan, Lu-Yu Hwang, James L. Abbruzzese, Salvatore V. Pizzo, Tur‐Fu Huang, Michael B. Wallace, Hao-Sen Chiang, Charlotte W. Pratt and Paul A. Roche and has published in prestigious journals such as Hepatology, The American Journal of Gastroenterology and Journal of Leukocyte Biology.

In The Last Decade

Mark W. Swaim

9 papers receiving 834 citations

Hit Papers

Risk factors for hepatocellular carcinoma: Synergism of a... 2002 2026 2010 2018 2002 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark W. Swaim United States 9 532 411 188 148 104 9 860
Kazuo Tarao Japan 19 778 1.5× 858 2.1× 186 1.0× 75 0.5× 107 1.0× 74 1.4k
P J Winwood United Kingdom 9 396 0.7× 494 1.2× 128 0.7× 38 0.3× 105 1.0× 13 833
Frederick K. Askari United States 12 427 0.8× 517 1.3× 241 1.3× 52 0.4× 99 1.0× 26 1.1k
Jaswinder Singh Maras India 15 366 0.7× 248 0.6× 239 1.3× 112 0.8× 57 0.5× 61 749
Raffaella Vecchione Italy 15 871 1.6× 565 1.4× 260 1.4× 132 0.9× 118 1.1× 36 1.4k
Akihiro Deguchi Japan 15 233 0.4× 385 0.9× 147 0.8× 71 0.5× 121 1.2× 41 681
David Fallik France 9 322 0.6× 211 0.5× 178 0.9× 438 3.0× 130 1.3× 12 811
Peri Kocabayoglu Germany 13 503 0.9× 448 1.1× 215 1.1× 46 0.3× 61 0.6× 20 985
Hiroaki Okuda Japan 19 979 1.8× 1.1k 2.7× 205 1.1× 137 0.9× 207 2.0× 34 1.6k
Masaya Shigeno Japan 9 278 0.5× 287 0.7× 168 0.9× 61 0.4× 121 1.2× 13 599

Countries citing papers authored by Mark W. Swaim

Since Specialization
Citations

This map shows the geographic impact of Mark W. Swaim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Swaim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Swaim more than expected).

Fields of papers citing papers by Mark W. Swaim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Swaim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Swaim. The network helps show where Mark W. Swaim may publish in the future.

Co-authorship network of co-authors of Mark W. Swaim

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Swaim. A scholar is included among the top collaborators of Mark W. Swaim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Swaim. Mark W. Swaim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Wallace, Michael B. & Mark W. Swaim. (2003). Transjugular Intrahepatic Portosystemic Shunts through Hepatic Neoplasms. Journal of Vascular and Interventional Radiology. 14(4). 501–507. 23 indexed citations
2.
Hassan, Manal M., et al.. (2002). Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 36(5). 1206–1213. 574 indexed citations breakdown →
3.
Swaim, Mark W., et al.. (2000). Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. The American Journal of Gastroenterology. 95(11). 3218–3224. 67 indexed citations
4.
Eloubeidi, Mohamad A., et al.. (2000). Case Report: Reversible Nefazodone-Induced Liver Failure. Digestive Diseases and Sciences. 45(5). 1036–1038. 15 indexed citations
5.
Swaim, Mark W., et al.. (1995). Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin. Breast Cancer Research and Treatment. 33(3). 225–235. 14 indexed citations
6.
Chiang, Hao-Sen, Mark W. Swaim, & Tur‐Fu Huang. (1994). Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin. British Journal of Haematology. 87(2). 325–331. 28 indexed citations
7.
Pratt, Charlotte W., Mark W. Swaim, & Salvatore V. Pizzo. (1989). Inflammatory Cells Degrade Inter-α Inhibitor to Liberate Urinary Proteinase Inhibitors. Journal of Leukocyte Biology. 45(1). 1–9. 27 indexed citations
8.
Pizzo, Salvatore V., Mark W. Swaim, Paul A. Roche, & Steven L. Gonias. (1988). Selectivity and stereospecificity of the reactions of dichlorodiammineplatinum(II) with three purified plasma proteins. Journal of Inorganic Biochemistry. 33(1). 67–76. 31 indexed citations
9.
Swaim, Mark W. & Salvatore V. Pizzo. (1988). REVIEW: Methionine Sulfoxide and the Oxidative Regulation of Plasma Proteinase Inhibitors. Journal of Leukocyte Biology. 43(4). 365–379. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026